Dementia and Movement Disorders Market Size, Share, Trends, Growth and Forecast 2028

Industry Prospective:

The global dementia and movement disorders market size is estimated to grow to about USD 7.45 billion by 2028, with a compound annual growth rate (CAGR) of approximately 6.5 percent over the forecast period. The report analyzes dementia and movement disorders market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in dementia and movement disorders market.

Request Free Sample

Dementia and Movement Disorders Market: Overview

Dementia is a broad spectrum of mental diseases that, over time, cause a person's capacity for thought and memory to decrease. The causes of dementia have not yet been discovered, despite advances in science and medicine. As a result, the illness is solely managed on a symptomatic basis. However, it is well established that numerous movement disorders, including Parkinson's, can trigger dementia. They can happen to anyone of any age, from newborns to the elderly. While symptoms in some cases are limited to issues with motor control, in others they can also impact cognitive and autonomic processes.

The market share growth by the movement disorders segment will be significant during the forecast period. Movement disorders refer to a group of neurological conditions that primarily affect a person's ability to produce and control movements. Movement disorders can significantly impact an individual's ability to perform daily activities and lead a fulfilling life. Effective medications that can manage symptoms and enhance functional abilities are in demand to improve the quality of life for those affected.

COVID-19 Impact:

The global dementia and movement disorders market witnessed a drop in revenue with the outbreak of Covid-19. Due to their increased susceptibility to COVID-19, senior individuals with diseases like Alzheimer's disease saw a decrease in their number of clinical visits. However, the prevalence of COVID-19 patients in the country decreased in 2021 as a result of the development of COVID-19 vaccinations. Thus, with accessibility to hospitals and clinics being resumed along with the relaxation of COVID-19-related limitations, the demand for dementia and movement disorders therapy medications increased once again. The global market is therefore anticipated to increase throughout the projected period as a result of these reasons.

Request Free Sample

Dementia and Movement Disorders Market: Growth Drivers

Rising geriatric population to fuel the market expansion.

The rising geriatric population is one of the main factors promoting the growth of global dementia and movement disorders market. Children under the age of five have been outnumbered by persons 60 years and older in the year 2020. Eighty percent of the world's elderly population will reside in low- and middle-income nations by 2050. On an account of this, it is anticipated that there would be 78 million cases of dementia worldwide by 2030 and 139 million cases by 2050. Globally rising senior populations will raise the likelihood that people may have neurological conditions like dementia, which will increase demand for dementia medications and propel the market.

Dementia and Movement Disorders Market: Restraints

High costs associated with the treatment to hamper the market growth

The growing financial burden of neurological illnesses is one of the main reasons impeding the market's expansion for treatments for dementia and movement disorders. One of the 10 major leading causes of mortality in the US, according to the CDC, is Alzheimer's disease. As a result, the US has a significant need for Alzheimer's disease treatment. Patients in the US, however, face difficulties as a result of rising treatment expenses. The Michael J. Fox Foundation and other national organizations in the US completed and released research titled The Economic Burden of Parkinson's Disease. According to the report, Parkinson's disease costs the US government, families, and people a total of $51.9 billion every year. Thus, high costs and increasing economic burden are the factors hindering the growth of global market.

Dementia and Movement Disorders Market: Opportunities

Heavy investments in R&D activities to foster market expansion during the forecast period

Dementia correlated with Alzheimer's disease is anticipated to see growth over the course of the forecast period as a result of increasing disease-modifying therapeutic R&D activities and increased investments by major players in clinical trials of cutting-edge treatment alternatives. In addition to this, mergers and acquisitions as well strategic collaborations by big pharma for business expansion are also likely to generate numerous opportunities for the growth of global dementia and movement disorders market during the forecast period.

Dementia and Movement Disorders Market: Challenges

Stringent regulatory framework to act as a challenge to market growth

Even though there is a lot of work being done to help those with dementia and movement disorders, the market is facing profound challenges due to the regulatory framework's strictness, the lengthy approval process for drugs, the lack of funding for research & development, and the inadequate therapeutic management techniques. Additionally, the majority of disease-treatment medications fail Phase III testing, rendering efforts futile and reverting the issue of treating these disorders to its original state.

Dementia and Movement Disorders Market: Segmentation

The global dementia and movement disorders market is categorized based on type, drug class, route of administration, end use, and region. Based on the type, the market is fragmented into progressive dementia, movement disorder, and other neurological abnormalities. Glutamate inhibitors, acetylcholinesterase inhibitors, MAO inhibitors, and others are included in the drug class segment. The route of administration market comprises parenteral and oral. The end-use segment is classified into hospitals, clinics, and others.

During the anticipated period, the MAO inhibitors market share will expand significantly in terms of treating dementia and movement disorders. MAO inhibitors are utilized as monotherapy in initial Parkinson's disease or as an additional treatment in individuals with motor-related Parkinson's disease symptoms due to their excellent effectiveness and specificity. Thus, it is anticipated that the use of MAO inhibitors would rise as Parkinson's disease and other associated conditions become more common.

Application Analysis 

Movement disorders

The market share growth by the movement disorders segment will be significant during the forecast period. Movement disorders refer to a group of neurological conditions that primarily affect a person's ability to produce and control movements. Movement disorders can significantly impact an individual's ability to perform daily activities and lead a fulfilling life. Effective medications that can manage symptoms and enhance functional abilities are in demand to improve the quality of life for those affected.

Pharmaceutical companies, in collaboration with researchers and healthcare providers, are actively working on developing new medications and refining existing treatments to meet the growing demand for effective drugs that address various movement disorders. Emerging discoveries about movement disorder disease mechanisms are creating demand for medications that can more effectively intervene in the disease process, which is expected to propel the growth of the global dementia and movement disorder treatment market during the forecast period.

Drug Class Analysis 

MAO inhibitors

Monoamine oxidase inhibitors (MAOIs) are a class of drugs that block the actions of one or both MAO enzymes such as monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). MAO-B is a flavin adenine dinucleotide (FAD)-dependent mitochondrial enzyme. It is one of the two subtypes of the major monoamine metabolizing enzyme that regulates the levels of several chemicals in the brain, including the neurotransmitter dopamine. In addition, the literature on MAO-A inhibition in Parkinson's disease is comparatively scarce. However, various studies are being conducted to determine the role of this enzyme as a part of the therapeutic treatment of Parkinson's disease. Besides, MAO-B inhibitors such as selegiline, rasagiline, and safinamide are used to manage the early symptoms of the disease. Thus, the rising prevalence of Parkinson's disease and related disorders is expected to lead to an increase in the consumption of MAO inhibitors, thus driving market growth during the forecast period.

Acetylcholinesterase inhibitors

AChE is a hydrolytic enzyme that terminates acetylcholine (ACh)-mediated signal transmission by breaking down ACh in cholinergic synapses of the brain. ACh is a neurotransmitter that helps in the transmission of signals across nerve synapses. It is synthesized in nerve terminals and stored in vesicles. On receiving nerve impulses, nerve cells release ACh from vesicles, which reach the synaptic cleft and innervate postsynaptic and presynaptic receptors. The progressive death of cholinergic brain cells leads to dysfunction of cholinergic signal transmission and impairs the memory and behavior of a person, leading to Alzheimer's disease. In addition, AChE has been reported to be associated with senile plaques and other hallmarks of Alzheimer's disease. Thus, maintenance of adequate levels of choline by inhibiting AChE is a viable treatment approach for the management of the disease. AChE inhibitors act by inhibiting AChE in a competitive or non-competitive manner. Thus, such studies are expected to have a favorable impact on the growth of the global dementia and movement disorder treatment market during the forecast period.

Recent Developments

• In June 2022, in order to create and market AL01811, a new preclinical selective GBA2 inhibitor with first-in-class potential as an oral disease-modifying therapy for Parkinson's disease patients, Biogen and Alectos Therapeutics have engaged in a licensing and partnership agreement. Through this partnership, Biogen's ability to create treatments for movement disorders will be combined with Alectos' expertise in small-molecule therapies.
• In July 2021, GSK and Alector announced a strategic collaboration to produce progranulin-elevating monoclonal antibodies, AL001 and AL101, for a variety of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia.

Report Scope:

Dementia and Movement Disorders Market: Regional Landscape

North America to dominate the global market during the forecast period

Among the regions, North America is estimated to lead global dementia and movement disorders market. During the projection period, North America will account for 48% of market growth. The largest market in North America for the treatment of dementia and movement disorders are the US and Canada. Compared to the rest of the world, this region's market will increase more rapidly. Over the projection period, dementia and movement disorder therapy market would rise in North America due to the rising incidence of target illnesses including Parkinson's disease and Alzheimer's disease. On the other hand, due to government financial backing for enhancing quality healthcare infrastructure in numerous countries throughout the region and the intensifying campaigns for promoting consciousness of the therapies for dementia and movement disorders, the treatment procedures, and their effect on mental health, Asia Pacific may also present enormous opportunities for the market growth during the forecast period.

Dementia and Movement Disorders Market: Competitive Landscape

• Novartis AG
• Merck and Co. Inc.
• Biogen Inc.
• Bausch Health Companies Inc.
• Acorda Therapeutics Inc.
• AbbVie Inc.
• Johnson and Johnson
• GlaxoSmithKline Plc
• Eisai Co. Ltd.
• Teva Pharmaceutical Industries Ltd. 

Global dementia and movement disorders market is segmented as follows:

By Type

• Progressive Dementia
• Movement Disorder
• Other Neurological Abnormalities

By Application

• Glutamate inhibitors
• Acetylcholinesterase inhibitors
• MAO inhibitors
• Others

By Route of Administration

• Parenteral
• Oral

By End User

• Hospitals
  • Clinics
  • Others

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa